CenterBook Partners LP Has $94,000 Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

CenterBook Partners LP trimmed its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 88.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,836 shares of the company's stock after selling 88,899 shares during the period. CenterBook Partners LP's holdings in Day One Biopharmaceuticals were worth $94,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in Day One Biopharmaceuticals in the 4th quarter worth $27,000. Pallas Capital Advisors LLC acquired a new position in shares of Day One Biopharmaceuticals in the 1st quarter valued at $87,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Day One Biopharmaceuticals during the 1st quarter worth $88,000. Exchange Traded Concepts LLC grew its position in shares of Day One Biopharmaceuticals by 19.6% during the 1st quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company's stock valued at $117,000 after buying an additional 2,407 shares during the last quarter. Finally, Cerity Partners LLC acquired a new stake in shares of Day One Biopharmaceuticals in the 1st quarter worth approximately $119,000. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Trading Up 2.3%

Shares of Day One Biopharmaceuticals stock traded up $0.15 during midday trading on Tuesday, reaching $6.55. The company had a trading volume of 310,229 shares, compared to its average volume of 1,162,811. The stock has a fifty day simple moving average of $6.59 and a 200 day simple moving average of $8.57. Day One Biopharmaceuticals, Inc. has a 1-year low of $6.08 and a 1-year high of $16.76. The company has a market capitalization of $663.40 million, a price-to-earnings ratio of -9.18 and a beta of -1.27.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.11. The business had revenue of $30.76 million for the quarter, compared to analyst estimates of $30.28 million. Day One Biopharmaceuticals had a negative net margin of 42.66% and a negative return on equity of 14.98%. Sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on DAWN. Wedbush reissued an "outperform" rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Needham & Company LLC reduced their price objective on Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. HC Wainwright restated a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Finally, The Goldman Sachs Group cut their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research note on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $29.00.

Insider Activity

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 13,964 shares of the company's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $87,414.64. Following the completion of the sale, the chief executive officer directly owned 145,737 shares of the company's stock, valued at approximately $912,313.62. This represents a 8.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Charles N. York II sold 4,282 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $6.26, for a total transaction of $26,805.32. Following the completion of the transaction, the chief financial officer owned 265,231 shares of the company's stock, valued at approximately $1,660,346.06. The trade was a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,725 shares of company stock worth $167,299 over the last three months. 6.20% of the stock is currently owned by insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.